A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
You know, I haven't shipped anything. I have somebody else I have to do it. We have a person who's trained as a shipper, and they take care of it.
-
Okay. I want to go back to the DARPA question on PREEMPT. I'll show you this email, and I don't have another copy of it right now. But it is dated March 7, 2019. It's from Vineet Menarchery, and you have a couple of other folks on here from Autonomous Therapeutics. [Exhibit No. 3 shown.]
-
It says, "Ralph, I've been working on a DARPA proposal with Autonomous Therapeutics on MERS-CoV with a quick turnaround. They're funded for another DARPA project to generate therapeutic interfering particles, and are looking to apply their approach for MERS on this specific supplement call. We have been chatting for a few weeks, and they are interested in both in vitro and in vivo experiments with their MERS-CoV targeted TIPs. I am currently planning to work with them on the in vitro side, but suggest they talk directly to you about the DPPR 288/330 model."
-
Okay.
-
2026-04-10 09:00
Christina Salazar
Do you recognize this?
-
Within the contest of Vineet, yes.
-
Did you end up doing work with -- DC.Scheduling@LexitasLegal.com
-
I don't know. I don't believe that I ever had -- I mean, this is an easy thing for us to test, to see if we had money from them. But I'm 99 percent sure that we never received any money from this group. The other possibility would be that Vineet asked me to send him the mouse model. The 288/330 is the mouse model that I talked about for MERS earlier. And so if he had that agreement with them and he wanted it, he's a former postdoc, I would've sent it to him in a second.
-
Because I believe this is a PREEMPT11 funded.